医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging Expands Presence in Asia with First Installation in Hong Kong

2015年04月23日 AM01:56
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that the Department of Orthopaedics and Traumatology at the Chinese University of Hong Kong (CUHK) is the first hospital in Hong Kong to install the EOS® system.

Since its founding in 1982, the mission of CUHK’s orthopedics department has evolved into a commitment to provide the highest quality service in patient care, research and education. The department’s clinical work and research is considered among the best and has been published in more than 54 international medical journals, contributing to CUHK ranking among the top 100 medical schools in the world, according to Thompson Reuters’, “Times Higher Education World University Subjects Rankings”1.

The university’s decision to adopt an EOS® system was guided by the orthopaedic department’s emphasis on patient care and a strong commitment to ensure surgeons use industry leading equipment and innovative surgical planning and modeling services.

Marie Meynadier, CEO of EOS imaging, said, “The Chinese University of Hong Kong is ranked as a leading university for orthopedic care in Asia and we are thrilled by their decision to adopt EOS® for their diagnosis, planning and control imaging. This new installation will strengthen our growing presence in the important Asia-Pacific market where we are investing to deploy our technology.”

The EOS® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: July 21th, 2015

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

1 http://www.timeshighereducation.co.uk/world-university-rankings/2013-14/subject-ranking/subject/clinical-pre-clinical-health/institution/chinese-university-of-hong-kong

CONTACT

EOS imaging
Anne Renevot, CFO, +33 (0)1 55 25 61 24
investors@eos-imaging.com
or
NewCap
Financial
communication and investor relations
Sophie Boulila / Pierre
Laurent, +33 (0)1 44 71 94 91
eosimaging@newcap.fr
or
The
Ruth Group (US)

Press relations
Calvin Allen, 646-536-7002
callen@theruthgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表